CAMBRIDGE, Mass., Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following schedule of investor conferences:

•  Morgan Stanley 19^th Annual Global Healthcare Conference
   Virtual fireside chat at 2:45 p.m. ET on September 9
   
•  H.C. Wainwright 23^rd Annual Global Investment Conference
   On-demand presentation available at 7:00 a.m. ET on September 13
   
•  Cantor Fitzgerald Virtual Global Healthcare Conference 2021
   Virtual presentation at 2:00 p.m. ET on September 27

Where applicable, live webcasts of Akebia's fireside chats and presentations will be made available on the Investors section of the Company's website at    https://ir.akebia.com    .

 About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

 Akebia Therapeutics Contact
 Kristen K. Sheppard, Esq.
 ir@akebia.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-september-2021-investor-conference-schedule-301366758.html

SOURCE Akebia Therapeutics